سعر سيمبيكورت 320/9مكجم/جرعة تربوهيلر 60 جرعة 2024

Inhalation powder (Turbuhaler dry-powder inhaler) delivering budesonide 320 mcg and formoterol fumarate dihydrate 9 mcg per inhalation; 60 doses per inhaler.

• Regular (maintenance) treatment of asthma in adults and adolescents 12-17 yearsPopulation: Adults and adolescents 12-17 yearsemc (MHRA)
• Symptomatic treatment of COPD (FEV1 <70% predicted) with exacerbation historyPopulation: Adults >=18 yearsemc (MHRA)

• Common: oropharyngeal candidiasis, headache, tremor, palpitations, mild throat irritation, cough, dysphonia; pneumonia in COPD patients.International label, same formulation · emc (MHRA)

• Hypersensitivity to budesonide, formoterol or lactose (which contains small amounts of milk proteins).International label, same formulation · emc (MHRA)

• Do not stop abruptly; taper the dose. Patients should always have a rescue inhaler available.International label, same formulation · emc (MHRA)
• Systemic corticosteroid effects (adrenal suppression, growth retardation in children, reduced bone density, cataract, glaucoma) may occur especially at high doses for long periods; pneumonia risk in COPD.International label, same formulation · emc (MHRA)

• Potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors)Markedly increase budesonide plasma levels; concomitant use should be avoided.emc (MHRA)

• No clinical data for the combination in pregnancy; inhaled budesonide (~2000 pregnancies) showed no increased teratogenic risk. Use only when benefits outweigh risks, at the lowest effective budesonide dose.International label, same formulation · emc (MHRA)
• Budesonide is excreted in breast milk but no effects on the infant are anticipated at therapeutic doses; formoterol excretion unknown; consider only if benefit exceeds risk.International label, same formulation · emc (MHRA)